PIIND2026-01-012026-03-31PIIND2026-03-31PIIND2025-03-31PIIND2025-04-012026-03-31PIIND2026-01-012026-03-31in-capmkt:OtherExpenses1MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses2MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses3MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses4MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses5MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses6MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses7MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses8MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses9MemberPIIND2026-01-012026-03-31in-capmkt:OtherExpenses10MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses1MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses2MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses3MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses4MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses5MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses6MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses7MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses8MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses9MemberPIIND2025-04-012026-03-31in-capmkt:OtherExpenses10MemberPIIND2026-03-31OtherNoncurrentFinancialAssetsDomain1PIIND2026-03-31OtherNoncurrentAssetsDomain1PIIND2026-03-31OtherNoncurrentAssetsDomain2PIIND2026-03-31OtherCurrentFinancialAssetsDomain1PIIND2026-03-31OtherCurrentAssetsDomain1PIIND2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1PIIND2026-03-31OtherNoncurrentFinancialLiabilitiesDomain2PIIND2026-03-31OtherCurrentFinancialLiabilitiesDomain1PIIND2026-03-31OtherCurrentFinancialLiabilitiesDomain2PIIND2026-03-31OtherCurrentLiabilitiesDomain1PIIND2026-01-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2025-04-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-03-31in-capmkt:ReportableSegments1MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-03-31in-capmkt:ReportableSegments2MemberPIIND2026-01-012026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-03-31in-capmkt:ReportableSegments3MemberPIIND2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1PIIND2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1PIIND2026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss1PIIND2026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss2PIIND2025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss1PIIND2025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss2PIIND2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares523642PIINDNOTLISTEDINE603J01030PI INDUSTRIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-192026-05-11INRMillionsQuarterlyFourth quarterMulti segment2026-05-1914:00:002026-05-1920:10:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated15652000000756000000164080000006690000000161000000-25200000022680000003700000010670000003416000000133870000003021000000-20000000300100000064700000035600000010030000000199800000000040000002002000000-406000000159600000015960000000152000000113.213.20013.213.21. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on May 19, 2026. <BR> <BR> 2. The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <BR> <BR> 3. The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) Plant Health Care de Mexico S. de R.L. de C.V. (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. <BR> <BR> 4. The figures for the March quarter are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of respective financial year. <BR> <BR> 5. The Company raised Rs 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs 19,750 Mn (net of expense of Rs 250 Mn), the Company invested Rs 18,419 Mn in its subsidiaries and Rs 1,331 Mn towards capital expenditure, thereby the entire QIP funds have been utilized during the year. <BR> <BR> 6. a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. <BR> <BR> Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company has renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement has resulted in a write-back of the contingent consideration of Rs 1,260 million, which has been presented under Exceptional Item during the quarter ended December 31, 2025. <BR> <BR> b) Pursuant to the notification issued by the Ministry of Labour and Employment, multiple existing labour legislations have been consolidated into a unified framework comprising four Labour Codes, collectively referred to as the New Labour Codes which became effective from November 21, 2025. The Group has reassessed its employee benefit obligations in accordance with the revised definition of Wages. Considering that this impact is driven by a regulatory change and is non-recurring in nature, accordingly, an incremental liability of Rs 209 Mn has been recognised as an Exceptional Item during the quarter ended December 31, 2025 and Rs 20 Mn during the quarter ended March 31, 2026. The Ministry is in the process of notifying related rules to the New Labour Codes and impact of those will be evaluated and accounted for in the period in which they are notified. <BR> 7. Segment information as per Ind AS 108 Operating Segments is as per Annexure I. <BR> 8. The Board of Directors at their meeting held on May 19, 2026 have recommended final dividend of Rs 10 per equity share, subject to the approval of the shareholders in the ensuring Annual General Meeting. With this, total dividend for the year (including interim dividend of Rs 5 per equity share paid during the year) is Rs 15 per share. <BR> 2025-04-012026-03-31AuditedConsolidated67137000000310700000070244000000299000000001680000000-324700000090770000001640000004066000000127310000005437100000015873000000103100000016904000000335200000040100000037530000000131510000000005700000013208000000-20400000013004000000130040000000152000000111215300000087.0687.060087.0687.06Net Impairment losses on financial assets83000000Power, Fuel & Water660000000Environment & Pollution Control Expenses263000000Freight & Cartage134000000Advertisement & Sales Promotion291000000Travelling and Conveyance355000000Legal & professional fees314000000Repairs & Maintenance363000000Laboratory & Testing Charges177000000Other expenses776000000Net Impairment losses on financial assets326000000Power, Fuel & Water2736000000Environment & Pollution Control Expenses1173000000Freight & Cartage440000000Advertisement & Sales Promotion988000000Travelling and Conveyance1131000000Legal & professional fees1096000000Repairs & Maintenance1409000000Laboratory & Testing Charges537000000Other expenses2895000000367830000007550000000602800000033860000002749000000315000000170000000171400000017310000005520000003960000005949000000012167000000132710000002319900000028330000001899000000012000000324000000586290000004151000000749470000001344370000001520000001121530000001123050000001123050000001490000000215900000036490000003320000003840000004365000000893000000725000000901300000097380000005706000000163370000009820000003970000005100000017767000000221320000001344370000001. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on May 19, 2026. <BR> <BR> 2. The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <BR> <BR> 3. The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) Plant Health Care de Mexico S. de R.L. de C.V. (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. <BR> <BR> 4. The figures for the March quarter are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of respective financial year. <BR> <BR> 5. The Company raised Rs 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs 19,750 Mn (net of expense of Rs 250 Mn), the Company invested Rs 18,419 Mn in its subsidiaries and Rs 1,331 Mn towards capital expenditure, thereby the entire QIP funds have been utilized during the year. <BR> <BR> 6. a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. <BR> <BR> Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company has renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement has resulted in a write-back of the contingent consideration of Rs 1,260 million, which has been presented under Exceptional Item during the quarter ended December 31, 2025. <BR> <BR> b) Pursuant to the notification issued by the Ministry of Labour and Employment, multiple existing labour legislations have been consolidated into a unified framework comprising four Labour Codes, collectively referred to as the New Labour Codes which became effective from November 21, 2025. The Group has reassessed its employee benefit obligations in accordance with the revised definition of Wages. Considering that this impact is driven by a regulatory change and is non-recurring in nature, accordingly, an incremental liability of Rs 209 Mn has been recognised as an Exceptional Item during the quarter ended December 31, 2025 and Rs 20 Mn during the quarter ended March 31, 2026. The Ministry is in the process of notifying related rules to the New Labour Codes and impact of those will be evaluated and accounted for in the period in which they are notified. <BR> 7. Segment information as per Ind AS 108 Operating Segments is as per Annexure I. <BR> 8. The Board of Directors at their meeting held on May 19, 2026 have recommended final dividend of Rs 10 per equity share, subject to the approval of the shareholders in the ensuring Annual General Meeting. With this, total dividend for the year (including interim dividend of Rs 5 per equity share paid during the year) is Rs 15 per share. <BR> Other non-current financial assets1714000000Current Tax assets119000000Other non-current assets277000000Other current financial assets324000000Other current assets4151000000Lease Liabilities722000000Other non-current financial liabilities1437000000Lease Liabilities318000000Other current financial liabilities5388000000Other current liabilities982000000Agro Chemicals14612000000Pharma1048000000Inter segment adjustment0Agro Chemicals64168000000Pharma3005000000Inter segment adjustment015660000000671730000008000000360000001565200000067137000000Agro Chemicals3325000000Pharma-486000000Inter segment adjustment186000000Agro Chemicals17975000000Pharma-2744000000Inter segment adjustment69900000030250000001593000000020000000-1031000000300500000016961000000Agro Chemicals119736000000Pharma14701000000Inter segment adjustment01344370000000134437000000Agro Chemicals18115000000Pharma4017000000Inter segment adjustment022132000000022132000000Notes : <BR> The business of the Group is divided into two segments as below: <BR> <BR> a) Agro chemicals: Agro chemicals includes Agchem exports (CSM), Domestic Agri Brands and Biologicals <BR> b) Pharma: Pharma comprises Contract Research & Development, Contract Development and Manufacturing of Active, key starting materials and intermediates used in pharmaceutical industry.164000000-2328000000-51320000000-594000000-600000028000000-3630000000-24090000000-3600000004066000000001330000001121000000138000000168000000020850000007000000-5120000000600000000-9370000000-851700000083870000000003647000000047400000000000000011400000011178000000000000000000000000208500000002844000000-6135000000000000001164000000132000000300000000227800000016400000000-1710000000-310500000015000000-309000000059230000002833000000Remeasurements gain/(loss) on defined benefits plans-20000000-20000000Remeasurements gain/(loss) on defined benefits plans6700000067000000-700000022000000Effective portion of gain/(loss) on cash flow hedges-1257000000Exchange difference on translation of foreign operations424000000-833000000Effective portion of gain/(loss) on cash flow hedges-2229000000Exchange difference on translation of foreign operations1200000000-1029000000-440000000-780000000-406000000-204000000AuditedtruePrice waterhouse chartered Accountants LLPtrue2026-11-30